Protalix Biotherapeutics Email Format

Biotechnology ResearchNorthern District, Israel201-500 Employees

Protalix Biotherapeutics operates in biotechnology with a focus on developing and commercializing recombinant therapeutic proteins produced through its ProCellEx plant cell-based expression system. It was the first to secure FDA approval for a protein produced in a plant cell-based suspension system, with taliglucerase alfa approved in May 2012 and subsequently cleared by regulators in other countries. The company licenses worldwide development and commercialization rights for taliglucerase alfa to Pfizer, excluding Brazil where Protalix retains full rights, and it is based in Karmiel, Northern District, Israel.
Its development pipeline comprises proprietary protein therapeutics aimed at established markets, including pegunigalsidase alfa for Fabry disease and other candidates such as alidornase alfa, PRX-115, and PRX-119. Recent developments include a collaboration with Secarna Pharmaceuticals to jointly develop candidates for rare renal indications, alongside an ongoing partnership with Chiesi Farmaceutici for Elfabrio.

Sign up for free to view info

Company overview Employee directory